Is Enliven Therapeutics (ELVN) a Buy After Its Upsized Offering and Positive Clinical Data

Related Articles

Why Did Medicus Pharma's Stock Crash After Positive Clinical Data

8 months ago

OrbiMed's $39 Million Sale: A Strategic Exit, Not a Bearish Signal, for Enliven Therapeutics

4 months ago

What Does Tandem Diabetes Care's Upsized Convertible Note Offering Mean for Investors

8 months ago

Enliven Therapeutics' Soaring Stock Faces a $570,000 Insider Reality Check

3 months ago

Category

You may also like

Stock News•2 months ago

Enliven's Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says

Enliven Therapeutics (ELVN) received an Outperform rating from William Blair on Tuesday, citing lead candidate ELVN-001's potential to disrupt the chronic myeloid leukemia treatment market.

ELVN

Share

Stock News•2 months ago

Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds

Bicara Therapeutics (BCAX) was upgraded to Buy after early phase 1 data for ficerafusp alfa showed promising median overall survival in head and neck cancer. The $500M cash position funds operations i...

BCAX

Share

Stock News•4 months ago

Evommune's Healthy Balance Sheet Buys Them Time For AD

Evommune's EVO756 CSU miss casts doubt on its pipeline, but a healthy balance sheet and positive Phase 2a AD data for EVO301 provide a potential catalyst.

EVO

Share